uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
The rationale for targeting TGF-beta in chronic liver diseases
Univ Bari, Dept Biomed Sci & Human Oncol, Sch Med, Bari, Italy..
Med Univ Vienna, Ctr Comprehens Canc, Div Inst Canc Res, Dept Med 1, Vienna, Austria..
Mannheim Heidelberg Univ, Fac Med, Dept Med 2, Heidelberg, Germany..
Bellvitge Biomed Res Inst IDIBELL, Barcelona, Spain..
Show others and affiliations
2016 (English)In: European Journal of Clinical Investigation, ISSN 0014-2972, E-ISSN 1365-2362, Vol. 46, no 4, 349-361 p.Article, review/survey (Refereed) PublishedText
Abstract [en]

BackgroundTransforming growth factor (TGF)- is a pluripotent cytokine that displays several tissue-specific biological activities. In the liver, TGF- is considered a fundamental molecule, controlling organ size and growth by limiting hepatocyte proliferation. It is involved in fibrogenesis and, therefore, in worsening liver damage, as well as in triggering the development of hepatocellular carcinoma (HCC). TGF- is known to act as an oncosuppressor and also as a tumour promoter in HCC, but its role is still unclear. DesignIn this review, we discuss the potential role of TGF- in regulating the tumoural progression of HCC, and therefore the rationale for targeting this molecule in patients with HCC. ResultsA considerable amount of experimental preclinical evidence suggests that TGF- is a promising druggable target in patients with HCC. To support this hypothesis, a phase II clinical trial is currently ongoing using a TGF- pathway inhibitor, and results will soon be available. ConclusionsThe identification of new TGF- related biomarkers will help to select those patients most likely to benefit from therapy aimed at inhibiting the TGF- pathway. New formulations that may provide a more controlled and sustained delivery of the drug will improve the therapeutic success of such treatments.

Place, publisher, year, edition, pages
2016. Vol. 46, no 4, 349-361 p.
Keyword [en]
EMT, galunisertib, HCC, targeting TGF-beta RI, TGF-beta, tumour progression
National Category
Cancer and Oncology
URN: urn:nbn:se:uu:diva-299081DOI: 10.1111/eci.12596ISI: 000373160900007PubMedID: 26823073OAI: oai:DiVA.org:uu-299081DiVA: diva2:948928
EU, European Research Council
Available from: 2016-07-14 Created: 2016-07-14 Last updated: 2016-07-14Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Moustakas, Aristidis
By organisation
Department of Medical Biochemistry and MicrobiologyLudwig Institute for Cancer Research
In the same journal
European Journal of Clinical Investigation
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 59 hits
ReferencesLink to record
Permanent link

Direct link